Table 4.
Concentrations of biomarker outcomes at baseline and change during 15 weeks
| Outcome | Baseline(Mean±SD) | Δ Baseline to Week 15(Mean ± SD) | Δ from Control(Mean ± SE) | P |
|---|---|---|---|---|
| Insulin, μU/mL | ||||
| Intervention | 8.5±15.0 | −5.4±16.8 | −7.7±3.5 | 0.004 |
| Control | 8.0±5.6 | 2.3±5.0 | ||
| Leptin, ng/mL | ||||
| Intervention | 43.1±26.4 | −12.8±26.9 | −7.3±4.0 | 0.04 |
| Control | 38.5±22.5 | −2.3±28.6 | ||
| Adiponectin, ng/mL | ||||
| Intervention | 99.2±43.5 | 14.7±51.6 | 26.2±15.4 | 0.09 |
| Control | 92.7±41.3 | −11.5±54.8 | ||
| C-Reactive Protein, ng/mL | ||||
| Intervention | 28.4±26.6 | −8.5±44.1 | −10.0±12.7 | 0.40 |
| Control | 41.0±33.0 | 1.5±44.2 | ||
| Interleukin-6, pg/mL | ||||
| Intervention | 2.2±1.2 | 0.3±1.6 | 0.6±0.4 | 0.24 |
| Control | 2.4±1.5 | −0.3±1.3 | ||
SD, standard deviation; SE, standard error. This analysis was conducted using the per-protocol (completers) analysis set, including n=23 for the intervention group and n=25 for the control group.